Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Home

Showing results (211-220 of 231) with videos related to

Pageof 24
Sort By:
The Journal of Clinical Endocrinology and Metabolism|November 10, 2009
Endothelial progenitor cells in subclinical hypothyroidism: the effect of thyroid hormone replacement therapyS K Abdul Shakoor, Ali Aldibbiat, Lorna E Ingoe, et al.
Diabetes Care|August 23, 2014
Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forumWilliam T Cefalu, John B Buse, Stefano Del Prato, et al.
Diabetologia|July 19, 2005
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocolP D Home, S J Pocock, H Beck-Nielsen, et al.
Lancet (London, England)|June 9, 2009
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trialPhilip D Home, Stuart J Pocock, Henning Beck-Nielsen, et al.
European Heart Journal|February 2, 2010
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trialMichel Komajda, John J V McMurray, Henning Beck-Nielsen, et al.
Diabetes Research and Clinical Practice|April 1, 2015
Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continentsPhilip D Home, Marie-Paule Dain, Nick Freemantle, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|February 24, 2006
Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetesS G Ashwell, S A Amiel, R W Bilous, et al.
Diabete & Metabolisme|June 1, 1982
A study of the comparative safety and efficacy of neutral soluble human (semi-synthetic) and porcine monocomponent insulin in non-diabetic subjectsD R Owens, M K Jones, A J Birtwell, et al.
Diabetes Technology & Therapeutics|February 4, 2016
Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 DiabetesMatthew C Riddle, Geremia B Bolli, Philip D Home, et al.
Diabetes Research and Clinical Practice|July 7, 2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapyPhilip D Home, Bo Ahrén, Jane E B Reusch, et al.
Pageof 24

Showing results (211-220 of 231) with videos related to

Sort By:
Pageof 24
The Journal of Clinical Endocrinology and Metabolism|November 10, 2009
Endothelial progenitor cells in subclinical hypothyroidism: the effect of thyroid hormone replacement therapyS K Abdul Shakoor, Ali Aldibbiat, Lorna E Ingoe, et al.
Diabetes Care|August 23, 2014
Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forumWilliam T Cefalu, John B Buse, Stefano Del Prato, et al.
Diabetologia|July 19, 2005
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocolP D Home, S J Pocock, H Beck-Nielsen, et al.
Lancet (London, England)|June 9, 2009
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trialPhilip D Home, Stuart J Pocock, Henning Beck-Nielsen, et al.
European Heart Journal|February 2, 2010
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trialMichel Komajda, John J V McMurray, Henning Beck-Nielsen, et al.
Diabetes Research and Clinical Practice|April 1, 2015
Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continentsPhilip D Home, Marie-Paule Dain, Nick Freemantle, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|February 24, 2006
Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetesS G Ashwell, S A Amiel, R W Bilous, et al.
Diabete & Metabolisme|June 1, 1982
A study of the comparative safety and efficacy of neutral soluble human (semi-synthetic) and porcine monocomponent insulin in non-diabetic subjectsD R Owens, M K Jones, A J Birtwell, et al.
Diabetes Technology & Therapeutics|February 4, 2016
Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 DiabetesMatthew C Riddle, Geremia B Bolli, Philip D Home, et al.
Diabetes Research and Clinical Practice|July 7, 2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapyPhilip D Home, Bo Ahrén, Jane E B Reusch, et al.
Pageof 24